Skip to content

Study of Impact of Air vs SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping

Study of the Impact of Air Versus SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02030262
Enrollment
32
Registered
2014-01-08
Start date
2013-12-31
Completion date
2016-02-29
Last updated
2016-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epiretinal Membrane

Brief summary

The purpose of this study is to determine if one of these gaz (air and sulfur hexafluoride) is better than the other in epiretinal membrane peeling surgery. Both are already used for this surgery and this study will tell us if one is better than the other.

Interventions

PROCEDUREEpiretinal membrane peeling with fluid-air exchange

The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.

PROCEDUREEpiretinal membrane peeling with fluid-SF6 exchange

The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.

Sponsors

CHU de Quebec-Universite Laval
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of epiretinal membrane with corresponding optical coherence tomography * ETDRS visual acuity worse or equal to 20/30 * Adult able to give consent

Exclusion criteria

* Diagnosis of age-related macular degeneration * Opacity blocking the fundus visualisation * Presence of active intraocular inflammation * Presence of intraocular tumor * Presence of retinal detachment

Design outcomes

Primary

MeasureTime frame
Visual acuity6 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026